UCB Pharma: Making Up for Lost Time
Executive SummaryPatent expiries across Europe of blockbuster allergy drug Zyrtec have hit UCB Pharma hard: the drug accounts for half of the mid-sized Belgian firm's revenues. Thus far, follow-on Xyzal has done poorly, prompting critics to accuse the group of complacency and lack of planning. But UCB has woken up. With some new senior pharma executives on board, it is determined to defend Xyzal-and its entire franchise-with strong clinical trial data; data which it hopes will also help convince governments, keen to de-reimburse antihistamines altogether, that allergy is a serious disease. Yet even if successful, this won't be enough to fill the Zyrtec gap. UCB needs to continue to push its promising anti-epileptic Keppra, and to cut its teeth in the in-licensing game.
You may also be interested in...
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.
Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Looking back at significantly sized acquisitions over just five years reveals that half of 2014’s acquisitions can already be judged as outright failures or, at best, questionable. But some lessons can be learned from dud deals.